Global Trial in APG2575 for Patients With CLL/SLL

June 16, 2026 updated by: Ascentage Pharma Group Inc.

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Approximately 440 patients will be enrolled, the patients who meet the eligibility criteria will be randomized in a 1:1 ratio to investigational arm (lisaftoclax in combination with a BTK inhibitor) or the control arm (BTK inhibitor alone). These patients with CLL/SLL have been on BTKi monotherapy and meet all other protocol required eligibility criteria.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
400

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Australia
      • Gosford, Australia, 2250
        • Completed
        • Ascentage Investigative Site
      • Perth, Australia, 6000
        • Completed
        • Ascentage Investigative Site
      • Westmead, Australia, 2145
        • Completed
        • Ascentage Investigative Site
  • Belgium
      • Ghent, Belgium, 9000
        • Recruiting
        • Ascentage Investigative Site
      • La Louvière, Belgium, 7100
        • Recruiting
        • Ascentage Investigative Site
      • Leuven, Belgium, 3000
        • Recruiting
        • Ascentage Investigative Site
      • Ottignies, Belgium, 1349
        • Recruiting
        • Ascentage Investigative Site
      • Roeselare, Belgium, 8800
        • Recruiting
        • Ascentage Investigative Site
  • Bulgaria
      • Sofia, Bulgaria, 1407
        • Recruiting
        • Ascentage Investigative Site
      • Sofia, Bulgaria, 1431
        • Recruiting
        • Ascentage Investigative Site
      • Sofia, Bulgaria, 1756
        • Recruiting
        • Ascentage Investigative Site
      • Sofia, Bulgaria, 1797
        • Recruiting
        • Ascentage Investigative Site
  • Canada
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3S 0H6
        • Recruiting
        • Ascentage Investigative Site
  • China
      • Guangzhou, China, 510090
        • Recruiting
        • Ascentage Investigative Site
    • Anhui
      • Hefei, Anhui, China, 230031
        • Recruiting
        • Ascentage Investigative Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100005
        • Recruiting
        • Ascentage Investigative Site
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Recruiting
        • Ascentage Investigative Site
    • Guangdong
      • Foshan, Guangdong, China, 528000
        • Recruiting
        • Ascentage Investigative Site
      • Guangzhou, Guangdong, China, 510050
        • Recruiting
        • Ascentage Investigative Site
    • Guangxie
      • Nanning, Guangxie, China, 530022
        • Recruiting
        • Ascentage Investigative Site
    • Henan
      • Zhengzhou, Henan, China, 450003
        • Recruiting
        • Ascentage Investigative Site
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Recruiting
        • Ascentage Investigative Site
    • Hunan
      • Chenzhou, Hunan, China, 423000
        • Recruiting
        • Ascentage Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • Ascentage Investigative Site
      • Suzhou, Jiangsu, China, 215026
        • Recruiting
        • Ascentage Investigative Site
      • Wuxi, Jiangsu, China, 214023
        • Recruiting
        • Ascentage Investigative Site
    • Jiangxi
      • Nanchang, Jiangxi, China, 330008
        • Recruiting
        • Ascentage Investigative Site
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Recruiting
        • Ascentage Investigative Site
    • Shandong
      • Binzhou, Shandong, China, 256600
        • Recruiting
        • Ascentage Investigative Site
    • Shanxi
      • Taiyuan, Shanxi, China, 030013
        • Recruiting
        • Ascentage Investigative Site
    • Sichuan
      • Luzhou, Sichuan, China, 646099
        • Recruiting
        • Ascentage Investigative Site
      • Yibin, Sichuan, China, 644099
        • Recruiting
        • Ascentage Investigative Site
  • Czechia
      • Hradec Králové, Czechia, 500 05
        • Recruiting
        • Ascentage Investigative Site
  • France
      • Clermont-Ferrand, France, 63000
        • Recruiting
        • Ascentage Investigative Site
      • Le Mans, France, 72037
        • Recruiting
        • Ascentage Investigative Site
      • Lyon, France, 69373
        • Recruiting
        • Ascentage Investigative Site
      • Nantes, France, 44000
        • Recruiting
        • Ascentage Investigative Site
      • Nantes, France, 44277
        • Recruiting
        • Ascentage Investigative Site
      • Nîmes, France, 30029
        • Recruiting
        • Ascentage Investigative Site
      • Orléans, France, 45100
        • Recruiting
        • Ascentage Investigative Site
      • Poitiers, France, 86000
        • Recruiting
        • Ascentage Investigative Site
      • Pontoise, France, 95300
        • Recruiting
        • Ascentage Investigative Site
      • Strasbourg, France, 67091
        • Recruiting
        • Ascentage Investigative Site
      • Tours, France, 37000
        • Recruiting
        • Ascentage Investigative Site
  • Germany
      • Dresden, Germany, 01307
        • Recruiting
        • Ascentage Investigative Site
      • Dresden, Germany, 48149
        • Recruiting
        • Ascentage Investigative Site
      • München, Germany, 81377
        • Recruiting
        • Ascentage Investigative Site
  • India
      • Puducherry, India, 605006
        • Recruiting
        • Ascentage Investigative Site
    • Gujarat
      • Gandhinagar, Gujarat, India, 382428
        • Recruiting
        • Ascentage Investigative Site
    • Haryana
      • Gurugramam, Haryana, India, 122001
        • Recruiting
        • Ascentage Investigative Site
      • Gurugramam, Haryana, India, 122002
        • Recruiting
        • Ascentage Investigative Site
      • Jhajjar, Haryana, India, 124105
        • Recruiting
        • Ascentage Investigative Site
    • Karnataka
      • Bangalore, Karnataka, India, 560027
        • Recruiting
        • Ascentage Investigative Site
      • Mysuru, Karnataka, India, 570023
        • Recruiting
        • Ascentage Investigative Site
    • Maharashtra
      • Navi Mumbai, Maharashtra, India, 400614
        • Recruiting
        • Ascentage Investigative Site
      • Pune, Maharashtra, India, 411001
        • Recruiting
        • Ascentage Investigative Site
    • National Capital Territory of Delhi
      • Delhi, National Capital Territory of Delhi, India, 110085
        • Recruiting
        • Ascentage Investigative Site
    • New
      • New Delhi, New, India, 110017
        • Recruiting
        • Ascentage Investigative Site
    • New Delhi
      • New Delhi, New Delhi, India, 110017
        • Recruiting
        • Ascentage Investigative Site
      • New Delhi, New Delhi, India, 110029
        • Recruiting
        • Ascentage Investigative Site
      • New Delhi, New Delhi, India, 110076
        • Recruiting
        • Ascentage Investigative Site
    • Tamil Nadu
      • Madurai, Tamil Nadu, India, 625020
        • Recruiting
        • Ascentage Investigative Site
    • Telangana
      • Hyderabad, Telangana, India, 500033
        • Recruiting
        • Ascentage Investigative Site
    • West Bengal
      • Kolkata, West Bengal, India, 700014
        • Recruiting
        • Ascentage Investigative Site
      • Kolkata, West Bengal, India, 700054
        • Recruiting
        • Ascentage Investigative Site
  • Israel
      • Haifa, Israel, 31048
        • Recruiting
        • Ascentage Investigative Site
      • Haifa, Israel, 3109601
        • Recruiting
        • Ascentage Investigative Site
      • Jerusalem, Israel, 91120
        • Recruiting
        • Ascentage Investigative Site
      • Kfar Saba, Israel, 4428164
        • Recruiting
        • Ascentage Investigative Site
      • Tel Aviv, Israel, 62431
        • Recruiting
        • Ascentage Investigative Site
  • Italy
      • Aviano, Italy, 33081
        • Recruiting
        • Ascentage Investigative Site
      • Brescia, Italy, 25123
        • Recruiting
        • Ascentage Investigative Site
      • Cona, Italy, 44124
        • Recruiting
        • Ascentage Investigative Site
      • Genova, Italy, 16132
        • Recruiting
        • Ascentage Investigative Site
      • Lecce, Italy, 73100
        • Recruiting
        • Ascentage Investigative Site
      • Meldola, Italy, 47014
        • Recruiting
        • Ascentage Investigative Site
      • Milan, Italy, 20141
        • Recruiting
        • Ascentage Investigative Site
      • Milan, Italy, 20132
        • Recruiting
        • Ascentage Investigative Site
      • Padova, Italy, 35122
        • Recruiting
        • Ascentage Investigative Site
      • Piacenza, Italy, 29121
        • Recruiting
        • Ascentage Investigative Site
      • Ravenna, Italy, 48121
        • Recruiting
        • Ascentage Investigative Site
      • Reggio Emilia, Italy, 42123
        • Recruiting
        • Ascentage Investigative Site
      • Rimini, Italy, 47923
        • Recruiting
        • Ascentage Investigative Site
      • Roma, Italy, 00128
        • Recruiting
        • Ascentage Investigative Site
      • Roma, Italy, 00168
        • Recruiting
        • Ascentage Investigative Site
      • Torino, Italy, 10126
        • Recruiting
        • Ascentage Investigative Site
      • Udine, Italy, 33100
        • Recruiting
        • Ascentage Investigative Site
  • Poland
      • Bydgoszcz, Poland, 85-048
        • Recruiting
        • Ascentage Investigative Site
      • Krakow, Poland, 30-727
        • Recruiting
        • Ascentage Investigative Site
      • Lodz, Poland, 93-513
        • Recruiting
        • Ascentage Investigative Site
      • Skorzewo, Poland, 60-185
        • Recruiting
        • Ascentage Investigative Site
  • Romania
      • Bucharest, Romania, 022328
        • Recruiting
        • Ascentage Investigative Site
      • Cluj-Napoca, Romania, 400015
        • Recruiting
        • Ascentage Investigative Site
      • Timișoara, Romania, 300254
        • Recruiting
        • Ascentage Investigative Site
  • Russia
      • Kaluga, Russia, 246007
        • Active, not recruiting
        • Ascentage Investigative Site
      • Kazan', Russia, 420029
        • Active, not recruiting
        • Ascentage Investigative Site
      • Moscow, Russia, 115522
        • Active, not recruiting
        • Ascentage Investigative Site
      • Moscow, Russia, 123182
        • Active, not recruiting
        • Ascentage Investigative Site
      • Moscow, Russia, 125284
        • Active, not recruiting
        • Ascentage Investigative Site
      • Petrozavodsk, Russia, 185019
        • Active, not recruiting
        • Ascentage Investigative Site
      • Saint Petersburg, Russia, 197022
        • Active, not recruiting
        • Ascentage Investigative Site
      • Saint Petersburg, Russia, 197341
        • Active, not recruiting
        • Ascentage Investigative Site
      • Sochi, Russia, 354057
        • Active, not recruiting
        • Ascentage Investigative Site
      • Syktyvkar, Russia, 167904
        • Active, not recruiting
        • Ascentage Investigative Site
    • Kaluga Oblast
      • Saint Petersburg, Kaluga Oblast, Russia, 248008
        • Active, not recruiting
        • Ascentage Investigative Site
    • Kirov Oblast
      • Kirov, Kirov Oblast, Russia, 610027
        • Active, not recruiting
        • Ascentage Investigative Site
  • Slovakia
      • Bratislava, Slovakia, 833 10
        • Recruiting
        • Ascentage Investigative Site
      • Martin, Slovakia, 036 59
        • Recruiting
        • Ascentage Investigative Site
  • Spain
      • Barcelona, Spain, 08003
        • Recruiting
        • Ascentage Investigative Site
      • Barcelona, Spain, 08035
        • Recruiting
        • Ascentage Investigative Site
      • Palma de Mallorca, Spain, 07120
        • Recruiting
        • Ascentage Investigative Site
      • Santander, Spain, 39008
        • Recruiting
        • Ascentage Investigative Site
      • Valencia, Spain, 46015
        • Recruiting
        • Ascentage Investigative Site
  • Turkey (Türkiye)
      • Kepez, Turkey (Türkiye), 07025
        • Recruiting
        • Ascentage Investigative Site
      • Trabzon, Turkey (Türkiye), 31080
        • Recruiting
        • Ascentage Investigative Site
  • United Kingdom
      • Birmingham, United Kingdom, B15 2GW
        • Recruiting
        • Ascentage Investigative Site
      • Bournemouth, United Kingdom, BH7 7DW
        • Recruiting
        • Ascentage Investigative Site
      • Liverpool, United Kingdom, L7 8YA
        • Recruiting
        • Ascentage Investigative Site
      • London, United Kingdom, SW3 6JJ
        • Recruiting
        • Ascentage Investigative Site
      • Manchester, United Kingdom, M20 4BX
        • Recruiting
        • Ascentage Investigative Site
      • Stoke-on-Trent, United Kingdom, ST4 6QG
        • Recruiting
        • Ascentage Investigative Site
      • Swansea, United Kingdom, SA2 8QA
        • Recruiting
        • Ascentage Investigative Site
      • West Bromwich, United Kingdom, B71 4HJ
        • Recruiting
        • Ascentage Investigative Site
      • Wolverhampton, United Kingdom, WV10 0QP
        • Recruiting
        • Ascentage Investigative Site
  • United States
    • Arizona
      • Tuscon, Arizona, United States, 85742
        • Recruiting
        • Ascentage Investigative Site
    • California
      • Anaheim, California, United States, 92805
        • Recruiting
        • Ascentage Investigative Site
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Recruiting
        • Ascentage Investigative Site
      • Miami Beach, Florida, United States, 33140
        • Recruiting
        • Ascentage Investigative Site
    • Illinois
      • Peoria, Illinois, United States, 61615
        • Recruiting
        • Ascentage Investigative Site
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Ascentage Investigative Site
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Recruiting
        • Ascentage Investigative Site
    • North Carolina
      • Greenville, North Carolina, United States, 27834
        • Recruiting
        • Ascentage Investigative Site
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • Ascentage Investigative Site
        • Principal Investigator:
          • Nitin Jain, MD
      • Kingswood, Texas, United States, 77339
        • Recruiting
        • Ascentage Investigative Site
    • Virginia
      • Richmond, Virginia, United States, 23298
        • Recruiting
        • Ascentage Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months
  3. ECOG Performance Status grade 0-2

  4. Adequate bone marrow function independent of growth factor or transfusion support within 2 weeks of screening initiation as follows:

    • Absolute neutrophil count ≥ 1.0 × 109/L
    • Platelet counts ≥ 75 × 109/L; in cases of thrombocytopenia
    • Total hemoglobin ≥ 9 g/dL,

  5. Adequate renal function

    • Creatinine clearance must be > 50 ml/min directly measured with 24hr urine collection or calculated according to the modified formula of Cockcroft and Gault (for men: GFR ≈ ((140 - age) x actual body weight)/(72 x creatinine), for women x 0.85) or an equally accurate method.
    • For patients with creatinine values within the normal range, the calculation of clearance is not necessary. Dehydrated patients with an estimated creatinine clearance less than 50 ml/min may be eligible if a repeat estimate after adequate hydration is > 50 ml/min.

  6. Adequate liver function as indicated by:

    • Total bilirubin ≤ 1.5 x ULN, except patients with known Gilbert's Syndrome
    • Aspartate aminotransferase (AST) ≤ 2.5 x the institutional ULN value
    • Alanine aminotransferase (ALT) ≤ 2.5 x the institutional ULN value,
    • International normalized Ratio (INR), Prothrombin Time (PT) or Activated Partial Thromboplastin time (APTT) ≤ 1.5×ULN.
  7. Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Arm 1
Combination therapy
Drug: lisaftoclax +BTK inhibitor
lisaftolax + BTK inhibitor
Active Comparator: Arm 2
mono therapy
Drug: BTK inhibitor
BTK inhibitor

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
PFS
Time Frame: 12 months
To evaluate the progression-free survival (PFS) of lisaftoclax in combination with BTKi compared with BTKi monotherapy in CLL/SLL patients previously treated with BTKi as determined by independent radiological review committee (IRC) using the iwCLL guidelines
12 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
overall survival
Time Frame: 12 months
To evaluate overall survival (OS) of lisaftoclax in combination with BTKi versus BTKi
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ascentage Pharma Group Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 20, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 31, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 23, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 26, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 27, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 18, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • APG2575CG301

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings